

Q2 FY24 QUARTERLY ACTIVITIES REPORT & APPENDIX 4C

Strong personal testing growth, UK acquisition & successful Phase I trial

Microba Life Sciences Limited (ASX: MAP) ("Microba" or the "Company"), a precision microbiome Company, is pleased to provide a summary of its activities for the quarter ended 31 December 2023.

Key Highlights

- **Successful acquisition of United Kingdom microbiome company, Invivo Clinical in December. Invivo unaudited Sales in 1H FY24* totalled \$4.39m AUD.**
- **Strong growth for MetaXplore healthcare test uptake. Over 1,000 Healthcare Professionals now registered.**
- **Advanced Infectious Disease testing technology MetaPanel™, scheduled for full national launch with Sonic Healthcare (ASX: SHL) in the current quarter.**
- **Inflammatory Bowel Disease Program – Successful Phase I Clinical Trial completed, demonstrating MAP 315 is safe and well tolerated.**
- **Autoimmune Program – Ginkgo Bioworks (NYSE:DNA) Stage 1 Screening completed. 35 Strains selected for Stage 2 Functional Screening, to be completed in the next quarter.**
- **Second Agreement executed with IFF (NYSE: IFF) to develop novel microbiome-based treatments for multiple forms of Allergy.**
- **1H FY24 unaudited Revenue totalled \$3.27m, up 52% on pcp.**
- **Q2 FY24 unaudited Revenue totalled \$2.19m[^], up 79% on pcp with Personal Testing & Supplements up 119%[^] to \$1.51m and Research Testing up 28% to \$0.68m.**
- **Q2 FY24 Cash Receipts totalling \$1.85m[^], up 4.1% on the prior quarter and up 15.2% on pcp.**
- **\$27.85m in Cash or Equivalents at 31 December 2023, not including an estimated \$6m FY23 R&D Tax Incentive.**

Commenting on the quarter, Microba's CEO, Dr Luke Reid, said:

"Microba's testing revenue continue to grow. We have been laying down the foundations to bring microbiome testing into healthcare and can see 2024 as a breakthrough year for the Company's testing business. The acquisition of Invivo Clinical supports our growth strategy with an established customer base in the United Kingdom and growth synergies. The upcoming launch of our world-first advanced Infectious Disease test MetaPanel together with Sonic Healthcare is expected to be a pivotal milestone."

"Microba's Therapeutic Development Programs continue to advance strongly. The Company successfully completed the Phase I clinical trial of lead candidate MAP 315 under the Company's Inflammatory Bowel Disease program, our Autoimmune program with Ginkgo Bioworks (NYSE: DNA) moved into the Second and Final Stage of the discovery program, and we've signed a Second Agreement to develop novel allergy treatments with IFF (NYSE: IFF). These results continue to validate Microba's therapeutic platform and the Company is set to continue advancement of these programs in 2024"

* United Kingdom Financial Year H1 1 April to 31 September 2023

[^] Invivo Clinical testing and supplement unaudited revenue and cash receipts included for the period of Microba's ownership, from 5 to 31 December 2023

Successful acquisition of Invivo Clinical

Microba acquired 100% of the issued share capital in UK registered company, Invivo Clinical Limited (Invivo) on December 5, 2023. Unaudited sales in H1 FY24 totalled \$4.39m AUD. The Invivo integration process is proceeding well.

Invivo is a pioneer in microbiome testing for healthcare professionals in the United Kingdom. Invivo has established a base of over 1,700 active customers, and an engaged list of additional 5,800 prospective customers. In addition to its leading position in Gastrointestinal microbiome testing services, Invivo has testing products spanning Vaginal, Oral and Urinary testing, together with a targeted set of evidence-based intervention formulations.

With more than 20,000 microbiome tests sold since 2020, Invivo reported revenue of A\$8.9 million for FY23 from testing and intervention product sales. Invivo has been self-funded from its generated cashflow since inception, with no external capital required, Invivo has been consistently operating cashflow positive.

The acquisition of Invivo aligns to Microba's core testing services growth strategy. The United Kingdom is a key market in the next phase of Microba's international testing services growth strategy. Acquiring a market leading position, customer and geographical base in the United Kingdom, together with Sonic Healthcare provides deep access to the entire UK healthcare market spanning private practice and the public NHS environment.

Growth for MetaXplore™ healthcare testing with Australian healthcare professionals

Q2 delivered MetaXplore growth:

- Over 2,700 tests sold
- Over 1,000 registered healthcare professional accounts

The MetaXplore™ test range was developed together with healthcare professionals to address a large addressable market with >30% of the population suffering from a disorder of gut-brain interaction (DGBI) related to the bowel¹, and >20% of the population estimated to suffer from a chronic health issue which may be influenced by their gut microbiome². The MetaXplore™ test range can be accessed in Australia via a healthcare professional, and is expected to be delivered into the United Kingdom through Invivo Clinical.

Microba's advanced infectious disease test MetaPanel™ with Sonic Healthcare scheduled for national launch

The MetaPanel product is scheduled for national launch with Sonic Healthcare in the current quarter. Previous plans were to open early Key Opinion Leader (KOL) access in December 2023, setting up for an initial NSW launch in Q3. The launch plan has now been upgraded together with Sonic Healthcare to a national launch beginning with VIC, NSW and QLD.

In July 2023, the first distribution agreement with Sonic Healthcare was signed to deliver Microba's advanced infectious disease testing technology MetaPanel™ Australia-wide through the Sonic Healthcare Australia Pathology network. Across the last two quarters Microba and Sonic have built technology integrations, logistics workflows, executed clinical test validation procedures, interviewed clinicians and developed marketing materials together in preparation to make the MetaPanel™ test clinically available to healthcare professionals. Further information will be shared on this product and the commercial opportunity over the coming quarters aligned to the launch of this product.

MetaPanel™ is an advanced accredited metagenomic diagnostic test which has been designed to identify a comprehensive panel of pathogenic microorganisms and genes to advance the standard of care in gastrointestinal infectious disease pathology. It is expected that this could represent a significant commercial opportunity for the Company with an estimated

¹ Estimated based on the prevalence of specific Disorders of the Gut-Brain Interaction across 26 countries (Av prevalence of 32.8% DOI: 10.1111/nmo.14594), and the proportion regularly seeking medical support with one or more doctor visit per month (Average 15.4% - DOI: 10.1053/j.gastro.2020.04.014).

² Estimated based on current literature on the understanding of the role of the microbiome in chronic disease (Vijay, Amrita, and Ana M. Valdes. (2022): 489-501. DOI: 10.1038/s41430-021-00991-6) and burden of these chronic diseases (Australian Bureau of Statistics (2020-21), *Health Conditions Prevalence*, ABS Website, accessed 20 March 2023.).

initial target market of over 16 million patients³ globally which are high-risk and susceptible to gastrointestinal infection, and receive routine testing for pathogens.

Growth in international revenue

International Personal Testing revenue up 321% on pcip, driven by growth of partner sales, expanding distribution partner network and recent Invivio Clinical acquisition. Major partner SYNLAB, Europe's largest medical diagnostic company, revenue up 115% on pcip, driven principally by sales in Spain, Italy and Hungary.

Inflammatory Bowel Disease Program – Successful Phase I Clinical Trial.

In December 2024, the Phase I clinical trial of lead drug candidate MAP 315 was completed on schedule, demonstrating it is safe and well tolerated at both low and high doses.

Summary of key MAP 315-001 study results:

- MAP 315 had a favourable safety and tolerability profile across both low and high dose cohorts.
- There were no clinically significant safety signals from safety assessments including ECGs and laboratory analysis of haematology, coagulation, clinical chemistry or urinalysis parameters.
- There was no evidence of translocation of MAP 315 into the bloodstream.
- There was no impact on inflammatory biomarkers.
- All participants completed the study and all dosing.
- All reported adverse events (AEs) were mild (e.g. headache), with a higher proportion reported in the placebo group and there were no AEs that lead to study discontinuation or drug withdrawal.
- Treatment related AEs were minimal, transient and comparable between the MAP 315 and placebo treatment groups.
- Ongoing assessment of faecal kinetics by metagenomic analysis detects the presence of MAP 315 at the terminal 28-day analysis timepoint, 14 days after the completion of dosing, indicating the ability to successfully deliver live MAP315 into the gastrointestinal tract.

Recent preclinical characterisation data, together with these Phase I clinical study results provide strong positive support for continuing to advance the clinical development of MAP 315 for the treatment of Ulcerative Colitis. Data from the trial is expected to be formulated and submitted for peer review publication. Preparation for a Phase 2 trial is well advanced, and the team are active in market exploring options in relation to the Phase 2 strategy.

MAP 315 is being developed for the treatment of Ulcerative Colitis (UC), a debilitating form of Inflammatory Bowel Disease (IBD) with >50% of patients unable to achieve sustained remission with current standard of care. The market for UC treatment was valued at US\$7.5b in 2020 and is forecast to grow to US\$10.8b by 2030⁴.

The Phase I trial is a randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics of MAP 315 in healthy adults. The trial involves 32 healthy participants and is being conducted by Nucleus Network, utilising their world-class clinical trial facilities in Melbourne.

IBD is a term for conditions that cause prolonged inflammation of the digestive tract and now affects more than 7 million

³ Estimated based on the global number of immuno-compromised patients and other patients at high risk for gastrointestinal infection (>8.1m global and >68k Australian chemotherapy treated solid tumour cancer patients, and >1.1m global and >8k Australian haematological cancer patients DOI:[https://doi.org/10.1016/S1470-2045\(19\)30163-9](https://doi.org/10.1016/S1470-2045(19)30163-9) & <https://www.aihw.gov.au/reports/cancer/cancer-in-australia-2021/summary>), (>3m global and 12k Australian dialysis patients DOI: [10.1038/s41581-022-00542-7](https://doi.org/10.1038/s41581-022-00542-7) & https://www.anzdata.org.au/wp-content/uploads/2019/09/c04_haemodialysis_2018_ar2019_v2.0_2020619.pdf & https://www.anzdata.org.au/wp-content/uploads/2021/09/c05_peritoneal_2020_ar_2021_Chapter_v1.0_20220530_Final.pdf), (>140k global and >1k Australian Organ Transplant patients per year <https://www.transplant-observatory.org/> & <https://www.health.gov.au/topics/organ-and-tissue-donation/organ-and-tissue-donation-in-australia>), (>3.5m global and >25k long stay ICU patients – estimate based on data from <https://ourworldindata.org/grapher/intensive-care-beds-per-100000> and other sources).

⁴ <https://www.nature.com/articles/d41573-021-00194-5> , <https://www.alliedmarketresearch.com/ulcerative-colitis-market>

people globally, with this number increasing each year⁵. UC is one of the two major forms of IBD which results in inflammation and ulcers (sores) in the digestive tract, causing a debilitating chronic condition. Patients are currently treated with anti-inflammatory and immunomodulatory medication to dampen the disease and control symptoms, often with significant side effects. These available treatment options commonly fail, with more than 50% of patients unable to achieve sustained remission⁶, which sees them experiencing regular episodes of inflammation, diarrhoea, bleeding and abdominal pain⁷. As many as 25% of patients require hospitalisation⁸.

Microba's novel drug candidate MAP 315 was originally identified using the Company's data-driven Therapeutic Platform, demonstrating that this previously unidentified novel bacterial species is commonly observed in healthy individuals but consistently deficient in individuals with IBD, and in particular UC. Subsequent pre-clinical investigation of MAP 315 through both *in vitro* and *in vivo* models demonstrated that MAP 315 promotes epithelial restitution and mucosal healing – biological activities that are associated with disease remission but not adequately addressed through existing therapy. MAP 315 provides a compelling commercial opportunity to fill a key gap in the current standard of care for UC treatment and represents a potential novel treatment paradigm for patients living with this debilitating disease.

Immuno-Oncology Program – Multiple immunological pre-clinical experiments completed to support candidate selection

Microba's Immuno-Oncology Program has completed multiple pre-clinical experiments for its therapeutic leads in across recent quarters confirming their anti-tumour activity. This involved testing in a refractory mouse model of melanoma, demonstrating a significant reduction in tumour volume. Subsequently, in a second experiment using an ICI responsive colon adenocarcinoma MC38 syngeneic mouse model, it was demonstrated again that Microba's therapeutic leads are able to significantly reduce tumour burden compared to ICI alone or controls. Further, immunological studies from the first model in the B16-F10 mouse tumour model completed over Q2 supported prior observations and strengthened results demonstrating activity consistent with induction of a specific and targeted immune response including:

- Changes in cytokine and chemokine profiles consistent with anti-tumour activity; and
- Identification of significantly enhanced immune cell infiltration by immunohistochemistry in microbiome and ICI treated animals compared to ICI alone

Microba continues to advance these studies with a goal to enable selection of a therapeutic candidate in the first half of 2024. This includes a partnership with Assoc Prof Fernando Guimaraes from The University of Queensland to allow a detailed examination of the immunological mechanism of action.

This program is targeting the development of a therapeutic to improve response rates in cancer patients receiving ICI therapy. Global ICI sales continue to grow, with Merck announcing sales of the market-leading drug Keytruda of US\$20.9b for calendar year 2022⁹.

While there have been considerable advances in the treatment options for melanoma, improvement of overall response rates and survival remain meaningful areas of opportunity. Furthermore, ICIs are used in a range of cancers beyond melanoma including lung, head and neck, breast, colon, cervical, and other types of cancer. With the ICI market being valued at over US\$30b with a >15% CAGR¹⁰, a microbiome-based adjuvant therapy that increases response to these drugs has the potential to become standard of care across a range of cancers, and therefore represents a substantial commercial opportunity for Microba.

There is an increasing body of literature supporting a key role for the microbiome in cancer¹¹. Cancer immunotherapy, and more specifically ICIs have become standard of care for a range of tumour types. However, despite their impact on cancer

⁵ [https://www.thelancet.com/journals/langas/article/PIIS2468-1253\(19\)30333-4/fulltext](https://www.thelancet.com/journals/langas/article/PIIS2468-1253(19)30333-4/fulltext).

⁶ <https://www.crohnscolitisfoundation.org/sites/default/files/2019-02/Updated%20IBD%20Factbook.pdf>.

⁷ Scribano, M.L. Adverse events of IBD therapies. *Inflamm Bowel Dis.* (2008). <https://doi.org/10.1002/ibd.20702>.

⁸ Pola, S. et al. Strategies for the care of adults hospitalized for active ulcerative colitis. *Clin Gastroenterol Hepatol.* (2012). <https://doi.org/10.1016/j.cgh.2012.07.006>.

⁹ <https://www.merck.com/news/merck-announces-fourth-quarter-and-full-year-2022-financial-results/>.

¹⁰ <https://au.finance.yahoo.com/news/immune-checkpoint-inhibitors-market-predicted-090000312.html>.

¹¹ Sepich-Poore et al. (2021). *The microbiome and human cancer*. DOI: 10.1126/science.abc4552.

treatment, up to 70% of patients do not respond to these drugs^{12,13} leaving a large, underserved patient population. Differences in the microbiomes of responders and non-responders to ICI treatment have been observed in international studies, and treatment of the microbiome using faecal microbiome transplants has demonstrated the ability to turn ICI non-responders into responders^{14,15}. This presents an important opportunity for Microba to leverage its proprietary Therapeutics Platform to identify the key components of the microbiome which drive that effect and develop an effective adjuvant therapy to improve ICI response. In addition to the potential large commercial opportunity for this program, these results provide another validation of Microba's unique ability to discover therapeutically active biology from the human microbiome through the Company's platform.

Autoimmune Disease Program – Stage 1 Screening Complete.

The autoimmune disease discovery program with partner Ginkgo Bioworks (NYSE: DNA) achieved a key milestone with completion of Stage 1 activity screening of lead strains.

Stage 1 activity screening analysed 182 strains selected through Microba's data driven drug discovery platform. These experiments have delivered a robust biological activity rate, including:

- 62% of strains displaying significant immunomodulatory activity; and
- 18% demonstrating significant impact on the inflammasome

The obtained data demonstrates that a significant number of the leads bacterial strains display potent anti-inflammatory and/or anti-fibrotic activities. 35 strains¹⁶ have now been selected to move into Stage 2 functional screening in the first quarter of 2024 for expected discovery program completion in Q4 FY24 to support lead candidate selection.

Microba's Autoimmune Disease program was established in partnership with Ginkgo Bioworks (NYSE: DNA) in FY22 following their strategic investment into Microba's IPO, and embodies a 2-year discovery program principally targeting three autoimmune disorders (lupus, psoriatic arthritis and autoimmune liver diseases). The partnership brought together Microba's unique ability to identify and isolate human gut bacteria associated with health together with the high-throughput microbial screening capabilities of Ginkgo Bioworks has created a powerful drug discovery workflow.

Autoimmune diseases are a family of more than 80 chronic and often life-threatening illnesses, which occur when the body's own immune system attacks the body's healthy cells, tissues and organs. Autoimmune conditions now impact around 5% of the population and their prevalence is rising¹⁷. In recent years, several studies have highlighted the role of the microbiome in the pathogenesis of autoimmune diseases¹⁸. The global market for autoimmune disease treatments was estimated to be US\$198b in 2023 and forecast to grow to US\$288b by 2028¹⁹.

Second agreement executed with IFF to develop novel microbiome-based treatments for multiple forms of allergy

In December, Microba signed a research agreement with IFF as part of an ongoing multistage research program between the parties to develop novel microbiome-based treatments for multiple forms of allergy.

The Research Agreement marks the second agreement between Microba and IFF, which is a follow up to the initial research services agreement executed on 9 November 2021. Under the Initial Agreement, for Stage 1, Microba completed the identification of lead species from which IFF was entitled to select under the Initial Agreement.

¹² Leonardi et al. (2020). *International Journal of Oncology*. DOI: 10.3892/ijo.2020.5088.

¹³ Wolchok et al. (2017). *New England Journal of Medicine*. DOI: 10.1056/NEJMoa1709684.

¹⁴ Baruch et al. (2020). *Science*. DOI: 10.1126/science.abb5920.

¹⁵ Davar et al. (2021). *Science*. DOI: 10.1126/science.abf3363.

¹⁶ Initial selection was 36. 1 has been removed for commercial opportunity considerations. As part of the screening further down selection will occur.

¹⁷ Fugger, L et al. Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases. *Cell*. (2020).

<https://doi.org/10.1016/j.cell.2020.03.007><https://doi.org/10.1016/j.cell.2020.03.007>

¹⁸ De Luca, F. and Shoenfeld, Y. The microbiome in autoimmune diseases. *Clin Exp Immunol*. (2019). <https://doi.org/10.1111/cei.13158>.

¹⁹ <https://www.prnewswire.com/news-releases/global-autoimmune-treatment-market-soars-to-288-32-billion-by-2028--driven-by-a-7-72-cagr-from-2023-301909189.html>

IFF has now selected a number of Project Species to move forward into Stage 2. The Stage 2 project is to complete the successful isolation of strains selected from Stage 1 and characterisation of those strains.

Over the term of the Research Agreement, IFF shall pay Microba approximately AUD \$924,150. Under the Research Agreement, IFF has an exclusive option to license strains for development and commercialization, which if executed may result in royalty payments to Microba.

Financial Update

Unaudited revenue for the December 2023 quarter totalled \$2.19m, representing 79% pcg growth with Personal Testing up 119% to \$1.51m and Research Testing up 28% to \$0.68m. Cash receipts for the December 2023 quarter totalled \$1.85m, up 4.1% on the prior quarter and up 15.2% on pcg. The Q2 FY24 numbers include Invivo Clinical's unaudited revenue and cash receipts for the period of Microba's ownership from 5 to 31 December 2023.

As at 31 December 2023, Microba had \$27.85m in cash or equivalents. During the quarter the Company invested \$4.04m into the advancement of its data driven drug discovery programs (IBD, Immuno-oncology, and Autoimmune Disease).

In accordance with Listing Rule 4.7C, payments made during the quarter to related parties and their associates included in item 6.1 of Appendix 4C was \$115,467 and included Director fees.

Use of Funds

In section 7.4 of the Microba Life Sciences Prospectus, the Company provided a proposed use of funds statement for 24 months from listing. The table below shows the use of funds from IPO to the end of the most recent quarter ended 31 December 2023, the table does doesn't include the estimated \$6m FY23 R&D Tax Incentive refund, which will be offset against the below line items.

Use of Funds	Q2 FY24	Prior Total	Total Expenditure	Prospectus
Global market penetration and sales growth	867	7,067	7,934	7,200
Data driven drug discovery	4,004	12,256	16,260	13,100
Platform technology advancement	786	2,039	2,825	2,500
Administrative and working capital	1,965	5,321	7,286	4,700
Costs of the offer	-	2,429	2,429	2,500
Total	7,622	29,112	36,734	30,000
Further capital – Sonic Healthcare (Nov 22)	-	17,237		-
Further capital – Invivo Acquisition ANREO (Nov 23)	-	19,997		

During Q2 FY24, overall expenditure remained in line with the estimated use of funds as set out in the Prospectus, noting that there has been an acceleration of the Company's activities, in particular the progression towards launch of Microba's advanced infectious disease test MetaPanel™ with Sonic Healthcare and the acquisition of Invivo Clinical, a pioneer in microbiome testing for healthcare professionals in the United Kingdom. This acceleration of activities has been enabled by the additional investment made by Sonic in November 2022 and the ANREO capital raising completed in November 2023.

This announcement has been authorised for release by the Board.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

E: Luke.Reid@microba.com

Investor / Media Relations

E: investor@microba.com

W: <https://ir.microba.com/>

[Join our Investor Mailing List](#)

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group, whose contact information is housed on the Investor Relations page of the Company's website.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Microba Life Sciences Limited, and controlled entities

ABN

82 617 096 652

Quarter ended ("current quarter")

31 December 2023

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (6 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	1,854	3,635
1.2 Payments for		
(a) research and development	(3,742)	(6,703)
(b) product manufacturing and operating costs	(904)	(1,637)
(c) advertising and marketing	(386)	(774)
(d) leased assets	(176)	(331)
(e) staff costs	(1,876)	(4,416)
(f) administration and corporate costs	(1,594)	(2,085)
1.3 Dividends received (see note 3)		
1.4 Interest received	214	437
1.5 Interest and other costs of finance paid	(6)	(12)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	18	26
1.8 Other (provide details if material)	-	-
1.9 Net cash from / (used in) operating activities	(6,598)	(11,860)
2. Cash flows from investing activities		
2.1 Payments to acquire or for:		
(a) entities	(9,574)	(9,574)
(b) businesses	-	-
(c) property, plant and equipment	(50)	(153)
(d) investments	-	-
(e) intellectual property	(831)	(1,554)
(f) other non-current assets	-	-

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(10,455)	(11,281)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	20,357	20,357
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(1,246)	(1,246)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(144)	(238)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	18,967	18,873

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	25,952	25,952
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(6,597)	(11,860)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(10,455)	(11,281)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (6 months) \$A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	18,967	18,873
4.5	Effect of movement in exchange rates on cash held	(21)	70
4.6	Cash and cash equivalents at end of period	27,846	21,754

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	27,846	25,952
5.2	Call deposits		
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	27,843	25,952

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	(115)
6.2	Aggregate amount of payments to related parties and their associates included in item 2	
<i>Note: Payments included in item 6.1 above relate to Director Fees and Consulting Fees paid to Directors of Microba Life Sciences Limited during the period.</i>		

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	(98)	(98)
7.4	Total financing facilities	(98)	(98)
7.5	Unused financing facilities available at quarter end		0
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	An unsecured insurance premium funding arrangement was entered into to finance the Group's annual insurance premiums. The balance originally drawn was \$479k, the balance at quarter end was \$98k, and is repayable over 11 equal monthly instalments, with a fixed interest rate of 3.89%.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	(6,597)
8.2	Cash and cash equivalents at quarter end (item 4.6)	27,846
8.3	Unused finance facilities available at quarter end (item 7.5)	0
8.4	Total available funding (item 8.2 + item 8.3)	27,846
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	4.2
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1	Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	N/A	
8.6.2	Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	N/A	
8.6.3	Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	N/A	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: **30 January 2024**

Authorised by: **The Board of Directors**
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.